These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 33248863

  • 1. Telehealth sustains patient engagement in OUD treatment during COVID-19.
    Langabeer JR, Yatsco A, Champagne-Langabeer T.
    J Subst Abuse Treat; 2021 Mar; 122():108215. PubMed ID: 33248863
    [Abstract] [Full Text] [Related]

  • 2. The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19.
    Hughto JMW, Peterson L, Perry NS, Donoyan A, Mimiaga MJ, Nelson KM, Pantalone DW.
    J Subst Abuse Treat; 2021 Jan; 120():108163. PubMed ID: 33298301
    [Abstract] [Full Text] [Related]

  • 3. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
    Hailu R, Mehrotra A, Huskamp HA, Busch AB, Barnett ML.
    JAMA Netw Open; 2023 Jan 03; 6(1):e2252381. PubMed ID: 36692880
    [Abstract] [Full Text] [Related]

  • 4. Patient Engagement in and Adaptations to Delivery of Outpatient Care for Opioid Use Disorder During the COVID-19 Pandemic.
    Zhou X, Thompson LK, Pagano A, Rahman N, Patel S, Gibson D, Ibrahim A, Casanova B, Schwartz RP, Vocci FJ, Clarke DE.
    Psychiatr Serv; 2024 Mar 01; 75(3):258-267. PubMed ID: 37855101
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic.
    Marshall SA, Siebenmorgen LE, Youngen K, Borders T, Zaller N.
    J Prim Care Community Health; 2024 Mar 01; 15():21501319241246359. PubMed ID: 38600789
    [Abstract] [Full Text] [Related]

  • 7. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
    Livingston NA, Sarpong A, Sistad R, Roth C, Banducci AN, Simpson T, Hyde J, Davenport M, Weisberg R.
    J Subst Use Addict Treat; 2024 Jan 01; 156():209188. PubMed ID: 37866437
    [Abstract] [Full Text] [Related]

  • 8. Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study.
    Bailey SR, Wyte-Lake T, Lucas JA, Williams S, Cantone RE, Garvey BT, Hallock-Koppelman L, Angier H, Cohen DJ.
    Subst Use Misuse; 2023 Jan 01; 58(9):1143-1151. PubMed ID: 37170596
    [Abstract] [Full Text] [Related]

  • 9. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
    Mattocks KM, Moore DT, Wischik DL, Lazar CM, Rosen MI.
    J Subst Abuse Treat; 2022 Aug 01; 139():108777. PubMed ID: 35346533
    [Abstract] [Full Text] [Related]

  • 10. Telehealth Utilization for Opioid Use Disorder: A Nationwide Analysis Before and After the COVID-19 Public Health Emergency Declaration.
    Lewis KN, Zhang D, Corrales G, Eswaran H, Hayes CJ, Gressler LE.
    Telemed J E Health; 2024 Jun 01; 30(7):e1980-e1989. PubMed ID: 38621153
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
    Lin LA, Zhang L, Kim HM, Frost MC.
    Am J Psychiatry; 2022 Oct 01; 179(10):740-747. PubMed ID: 35899380
    [Abstract] [Full Text] [Related]

  • 14. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
    Watson DP, Swartz JA, Robison-Taylor L, Mackesy-Amiti ME, Erwin K, Gastala N, Jimenez AD, Staton MD, Messmer S.
    BMC Public Health; 2021 Mar 31; 21(1):630. PubMed ID: 33789642
    [Abstract] [Full Text] [Related]

  • 15. Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.
    Yeo EJ, Kralles H, Sternberg D, McCullough D, Nadanasabesan A, Mayo R, Akselrod H, Catalanotti J.
    Harm Reduct J; 2021 Dec 09; 18(1):127. PubMed ID: 34886850
    [Abstract] [Full Text] [Related]

  • 16. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19.
    Lockard R, Priest KC, Gregg J, Buchheit BM.
    Subst Abus; 2022 Dec 09; 43(1):1150-1157. PubMed ID: 35499402
    [Abstract] [Full Text] [Related]

  • 17. Telemedicine for contraceptive counseling: Patient experiences during the early phase of the COVID-19 pandemic in New York City.
    Stifani BM, Smith A, Avila K, Boos EW, Ng J, Levi EE, Benfield NC.
    Contraception; 2021 Sep 09; 104(3):254-261. PubMed ID: 33861981
    [Abstract] [Full Text] [Related]

  • 18. Where Virtual Care Was Already a Reality: Experiences of a Nationwide Telehealth Service Provider During the COVID-19 Pandemic.
    Uscher-Pines L, Thompson J, Taylor P, Dean K, Yuan T, Tong I, Mehrotra A.
    J Med Internet Res; 2020 Dec 15; 22(12):e22727. PubMed ID: 33112761
    [Abstract] [Full Text] [Related]

  • 19. Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond.
    Pessar SC, Boustead A, Ge Y, Smart R, Pacula RL.
    JAMA Health Forum; 2021 Nov 15; 2(11):e213833. PubMed ID: 35647581
    [Abstract] [Full Text] [Related]

  • 20. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
    Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett M, Huskamp HA.
    J Subst Abuse Treat; 2020 Nov 15; 118():108124. PubMed ID: 32893047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.